Safety of long-term nucleos(t)ide treatment in chronic hepatitis B
Open Access
- 15 March 2012
- journal article
- Published by Informa Healthcare in Expert Opinion on Drug Safety
- Vol. 11 (3) , 357-360
Abstract
Currently, five nucleos(t)ide analogs (NAs) are approved for the treatment of chronic hepatitis B (CHB) infection. They are lamivudine, adefovir dipivoxil, telbivudine, entecavir (ETV) and tenofovir disoproxil fumarate (TDF). Two of them, ETV and TDF, are recommended as first-line treatment options. Their main advantages include excellent tolerability, antiviral potency and a high genetic barrier to resistance within medium duration treatment periods (2 – 6 years). In most patients, NAs need to be administered on a long-term basis. Several studies suggest that NAs long-term administration have been associated with low rates of serious adverse events (AEs), including lactic acidosis, renal function impairment, osteopenia and osteoporosis. Discontinuations due to AEs tended to be low in published randomized clinical trial and in the experience in clinical practice. NAs long-term use appears to be safe and effective; and in patients with advanced liver disease, despite preliminary concerning reports, their s...Keywords
This publication has 13 references indexed in Scilit:
- Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901Expert Opinion on Drug Safety, 2012
- Effectiveness of entecavir in chronic hepatitis B NUC-naive patients in routine clinical practiceInternational Journal Of Clinical Practice, 2011
- Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis BGastroenterology, 2011
- Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function†Hepatology, 2009
- Chronic hepatitis B: Update 2009 #Hepatology, 2009
- EASL Clinical Practice Guidelines: Management of chronic hepatitis BJournal of Hepatology, 2009
- Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis BNew England Journal of Medicine, 2008
- Entecavir Therapy for up to 96 Weeks in Patients With HBeAg-Positive Chronic Hepatitis BGastroenterology, 2007
- Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis BNew England Journal of Medicine, 2006
- A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis BNew England Journal of Medicine, 2006